Study S001009

GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07295223
Acronym: GALACTUS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 44
Start: 2025-12-30
Primary completion: 2026-08
Lead sponsor: Instituto Mexicano del Seguro Social
Conditions: Acute Myocardial Infarction With ST Elevation
Interventions: DRUG:Dapagliflozin 10 MG Oral Tablet; DRUG:Semaglutide (Rybelsus®)
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Inflammatory markers (high-sensitivity PCR) [24 weeks.]
Inflammatory markers (interleukin 6) [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.